Protagen AG Appoints Bernhard Kirschbaum as New Board Member
News Jan 08, 2015
Protagen AG has announced that the former Head of Research and Early Development of Merck Serono, Dr. Bernhard Kirschbaum, has joined the company’s Supervisory Board.
This news follows the recently announced strategic partnership between Protagen and QIAGEN, which will focus on pharma collaborations in the autoimmune space, an area where Dr. Kirschbaum has significant expertise.
Dr. Kirschbaum has served in executive positions at Hoechst, Aventis, Sanofi, and Merck Serono, and has a proven track record in preclinical and clinical R&D, with a special focus on autoimmune diseases and chronic inflammatory disorders. According to Dr. Kirschbaum, “Protagen offers a very solid, unique technology with broad application potential. It is of particular relevance for translational research, which remains a central topic in drug development. In many diseases, analyses at the protein level offer key insights and guidance on diseases status and drug development.”
Stefan Müllner, CEO of Protagen, added: “In order to become the leading provider of CDx for autoimmune therapy, it is imperative that we have meaningful insight into the R&D processes and interfaces of big pharma. The profound expertise Dr. Kirschbaum will bring to this role will provide us with valuable guidance, which will enable us to effectively expand our business within the growing CDx field.”
Nano-tech Diagnostic Can Indicate Cancer or Thrombotic Risk in One Drop of BloodNews
A team of international researchers led by Professor Martin Hegner, Investigator in CRANN and Trinity’s School of Physics, have developed an automated diagnostic platform that can quantify bleeding – and thrombotic risks – in a single drop of blood, within seconds.READ MORE
Doctors Rely on More Than Just Data During a DiagnosisNews
Computer scientists examine how a doctor’s “gut feeling” influences how many tests they order for patientsREAD MORE
Look Before You Flush: Cancer Campaign Encourages VigilanceNews
Be Clear on Cancer campaign urges public to check urine for blood and to inform the doctor ASAPREAD MORE